2024
Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis
Al Kasab S, Almallouhi E, Shu L, Kicielinski K, Salehi Omran S, Liebeskind D, Zubair A, Vedovati M, Paciaroni M, Antonenko K, Heldner M, de Havenon A, Henninger N, Yaghi S. Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis. Neurology Clinical Practice 2024, 15: e200381. PMID: 39399562, PMCID: PMC11464219, DOI: 10.1212/cpj.0000000000200381.Peer-Reviewed Original ResearchRisk of recurrent venous thromboembolismRecurrent venous thromboembolismCerebral venous thrombosisVenous thromboembolismFemale patientsVenous thrombosisBaseline characteristicsOutcome of cerebral venous thrombosisRate of recurrent venous thromboembolismProvoking factorsRare cause of strokeTransient provoking factorsKaplan-Meier survival analysisDuration of anticoagulationOutcomes of patientsMann-Whitney <i>Cause of strokeConsecutive patientsRare causeRecurrence rateMale patientsMulticenter studyRetrospective databaseStandard treatmentCox regressionAntithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Yaghi S, Shu L, Mandel D, Guerrero C, Henninger N, Muppa J, Affan M, Lodhi O, Heldner M, Antonenko K, Seiffge D, Arnold M, Omran S, Crandall R, Lester E, Mena D, Arauz A, Nehme A, Boulanger M, Touze E, Sousa J, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito M, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann J, Engelter S, Traenka C, de Sousa D, Soares M, Rosa S, Zhou L, Gandhi P, Field T, Mancini S, Metanis I, Leker R, Pan K, Dantu V, Baumgartner K, Burton T, Von Rennenberg R, Nolte C, Choi R, MacDonald J, Shahripour R, Guo X, Ghannam M, AlMajali M, Samaniego E, Sanchez S, Rioux B, Zine-Eddine F, Poppe A, Fonseca A, Baptista M, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin K, Kuohn L, Frontera J, Amar J, Giles J, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind D, Molaie A, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski K, Eltatawy A, Chervak L, Chulluncuy-Rivas R, Aziz Y, Bakradze E, Tran T, Rodrigo-Gisbert M, Requena M, Velez F, Gracia J, Mudassani V, de Havenon A, Vishnu V, Yaddanapudi S, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Siegler J, Mayer S, Willey J, Zubair A, Cheng Y, Sharma R, Marto J, Ferreira V, Klein P, Nguyen T, Asad S, Sarwat Z, Balabhadra A, Patel S, Secchi T, Martins S, Mantovani G, Kim Y, Krishnaiah B, Elangovan C, Lingam S, Quereshi A, Fridman S, Alvarado A, Khasiyev F, Linares G, Mannino M, Terruso V, Vassilopoulou S, Tentolouris V, Martinez-Marino M, Wall V, Indraswari F, Jamal S, Liu S, Alvi M, Ali F, Sarvath M, Morsi R, Kass-Hout T, Shi F, Zhang J, Sokhi D, Said J, Simpkins A, Gomez R, Sen S, Ghani M, Elnazeir M, Xiao H, Kala N, Khan F, Stretz C, Mohammadzadeh N, Goldstein E, Furie K. Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study. Stroke 2024, 55: 908-918. PMID: 38335240, DOI: 10.1161/strokeaha.123.045731.Peer-Reviewed Original ResearchCervical artery dissectionInverse probability of treatment weightingIschemic stroke riskIschemic strokeAntiplatelet therapyArtery dissectionCox regressionOcclusive dissectionCervical artery dissection patientsStroke riskProbability of treatment weightingBenefits of anticoagulationOptimal stroke prevention strategyStroke prevention strategiesReducing ischemic stroke riskAnticoagulant therapyAntithrombotic treatmentProspective studyCross-over approachRandomized trialsAnticoagulationCompare outcomesPrevention strategiesTreatment weightingHigh risk
2022
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial
Lang A, de Havenon A, Mac Grory B, Henninger N, Shu L, Furie K, Easton J, Kim A, Johnston S, Yaghi S. Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. European Stroke Journal 2022, 8: 328-333. PMID: 37021190, PMCID: PMC10069178, DOI: 10.1177/23969873221148224.Peer-Reviewed Original ResearchConceptsSubsequent ischemic strokeEffect of clopidogrelSubsequent stroke riskIschemic strokeMajor hemorrhagePoint trialStroke riskSmoking statusMinor Ischemic Stroke (POINT) trialSubgroup interaction analysesMultivariable Cox regressionMinor ischemic strokeIschemic stroke trialsEffect of smokingNon-significant trendNew TIACurrent smokersStroke trialsTobacco smokingCox regressionIndex eventSmokersSecondary analysisClopidogrelStroke
2021
Vessel Wall Enhancement on Black-Blood MRI Predicts Acute and Future Stroke in Cerebral Amyloid Angiopathy
McNally JS, Sakata A, Alexander MD, Dewitt LD, Sonnen JA, Menacho ST, Stoddard GJ, Kim S, de Havenon AH. Vessel Wall Enhancement on Black-Blood MRI Predicts Acute and Future Stroke in Cerebral Amyloid Angiopathy. American Journal Of Neuroradiology 2021, 42: 1038-1045. PMID: 33737266, PMCID: PMC8191668, DOI: 10.3174/ajnr.a7047.Peer-Reviewed Original ResearchConceptsCerebral amyloid angiopathyFuture ischemic strokeVessel wall enhancementIschemic strokeAmyloid angiopathyWall enhancementFuture strokeC-statisticVessel wall MRNew-onset neurologic symptomsInitial ischemic strokeStroke-free survivalAcute ischemic strokeIschemic stroke incidenceCAA patientsFinal regression modelNeurologic symptomsStroke incidenceCerebral amyloidCox regressionRetrospective studyRisk factorsMultivariable PoissonNegative participantsAngiopathy